期刊文献+

产帕曲星菌株的选育、抗菌物质纯化及结构鉴定

Breeding of partricin prodcing strain,purification of antifungal metabolite and its structure verification
下载PDF
导出
摘要 链霉菌SIPI-A.2020是本实验室分离保藏的一株可能产生帕曲星的放线菌,本文对此菌株培养与发酵、抗菌活性物质的分离纯化及其结构验证进行了研究。经过菌种选育与发酵条件优化,与出发菌株相比,主要发酵产物X的发酵效价提高89.3%;通过对发酵液的分离纯化,得到了HPLC纯度分别为96.3%和95.6%的两个组分,经进一步UV、MS、NMR等分析,验证其为帕曲星B和帕曲星A。 Streptomyces SIPI-A. 2020 is an actinomycetes strain separated and preserved in our laboratory, which possibly producing partricin. In this paper, the culture and fermentation conditions, the separation and purification antifungal metabolites and the structure verification were discussed. By the ways of strain breeding and cultural conditio is of ns optimization, the fermentation titer of the main product X was increased by 89. 3% compared to that of the original strain. Two components were obtained through the separation and purification of fermentation broth, and the HPLC purity was 96.3% and 95.6% respectively. Further analyses by the methods of UV, MS, NMR, the two components separated were verified as partricin A and partricin B, respectively
出处 《工业微生物》 CAS CSCD 2012年第4期7-12,共6页 Industrial Microbiology
基金 国家863计划课题(863-2006Aa02z414) "重大新药创制"科技重大专项(2009ZX09301-007) 上海市现场证物重点实验室开放课题(2011XCWZK09)
关键词 SIPI—A.2020 帕曲星 结构验证 菌种与发酵 分离纯化 SIPI-A. 2020 partricin structure verification strain and fermentation separation and purification
  • 相关文献

参考文献10

  • 1Bruzzese T, Ferraresi R. Treatment of dogs with partricin vaginal suppositories [ P]. US: 3773925. 1973 - 11 - 20.
  • 2Tweit R C, Pandey R C, Rinehart K L. Characterization of the antifungal and antiprotozoal antibiotic partficin and structural studies on partricin A and B[J]. J Antibiot (Tokyo), 1982, 35 (8) : 997-1012.
  • 3Bruzzese T, Signorini M, Ottoni F. Partricin derivatives [ P ]. US: 5298495 1994-03-29.
  • 4Ruozi P, Siccardi A G. Mepartricin, a polyene active on both Trichomonas and Gandida. Lack of mutagenic activity [ J ]. Farmaco Sci, 1978, 33(1) : 21 -25.
  • 5Golik J, Zielinski J, Borowski E. The structure of mepartricin A and mepartficin B[J]. J Antibiot (Tokyo), 1980, 33(8) : 904 - 907.
  • 6张致平.抗真菌药物研究进展[J].继续医学教育,2007,21(27):19-22. 被引量:2
  • 7Rimaroli C, Bonabello A, Sala P, Bruzzese T. Pharmacokinetics and tissue distribution of a new partriein A derivative ( N-dimeth- ylaminoacetyl-partricin A 2-dimethylaminoethylamide diaspartate) in mice[J]. J Pharm Sci. 2002, 91(5) : 1252 -1258.
  • 8Clemons K V, Stevens A D. Efficacy of the partricin derivative SPA-S-753 against systemic routine candidosis [ J ]. Journal of Antimicrobial Chemotherapy. 2001,47 (2) : 183 - 186.
  • 9Bruzzese T, Galmozzi M R, Ferrari V M, et al. Comparative pharrnacokinetics of three preparations of the new antifungal SPK- 843. Chemotherapy. 2001,47 (6) :387 - 395.
  • 10蒋正立,林建群.多烯类抗真菌药物的研究新进展[J].中国药业,2006,15(7):62-63. 被引量:16

二级参考文献12

  • 1冯敏,潘仕荣,吴伟荣.两性霉素B/聚乙二醇-聚谷氨酸苄酯纳米球溶血毒性的研究[J].中国药科大学学报,2004,35(3):263-266. 被引量:6
  • 2P Minodier,S Robert,G Noel.First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France[J].Arch Pediatr,2005,12(7):1 102-1 108.
  • 3Catherine Cordonnier,Thomas J Walsh,Mark Bresnik.Liposomal Amphotericin B (L-AMB) Is Superior to Amphotericin B Deoxycholate (AmB-d) in Preventing Breakthrough Fungal Infections in Patients with Prolonged Neutropenia and Fever:Results of a Sub-Group Analysis of an Empirical Antifungal Therapy Trial[J].Blood (ASH Annual Meeting Abstracts),2004,104(11):1336.
  • 4E Forestier,V Remy,O Lesens,et al.A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B,caspofungin and voriconazole[J].Eur J Clin Microbiol Infet al Dis,2005,24 (5):347-349.
  • 5Adedayo Adedoyin,Christine E Suenson,Lois E Bolcsak,et al.A pharmacokinetic Study of Amphotericin B Lipid Complex Infet al (Abelcet) in Patients with Definite or Probable Systemic Fungal Infet alions[J].Antimicrob Agents Chemother,2000,44:2 900-2 902.
  • 6M Subira,R Martino,L Gomez,et al.Low-dose amphotericin B lipid complex vs.conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized,controlled trial[J].Eur J Haematol,2004,72 (5):342 -344.
  • 7Rodrigo Martino,Bertrand Dupont,Helen Huckle,et al.No Signs of New Toxicity When Amphotericin B Lipid Complex (ABLC,ABELCET)and Caspofungin Are Used in Combination in the Treatment of FUO[J].Blood (Ash Annual Meeting Abseracts),2004,104 (11):5 077.
  • 8R Bowden,P Chandrasekar,MH White,et al.A double -blind,randomized,controlled trial of Amphoterincin B Colloidal Dispersion versus amphoterincin B for treatment of ivasive as pergillosis in immunocompromised patients[J].Clin Infet al Dis,2002,35 (4):359-366.
  • 9M Doubek,J Mayer,I Lauschova,et al.Comparison of the effect of amphotericin B desoxycholate and amphotericin B Colloidal dispersion on renal functions and renal morphology in rats[J].Nephrology (Carlton),2005,10 (1):57-62.
  • 10Karl V Clemons,Raymond A Sobel,Paul L Williams,et al.Comparative Toxicities and Pharmacokeintics of Intrathecal Lipid (Amphoterincin B Colloidal Dispersion) and Conventional Deoxycholate Formulations of Amphoterincin B in Rabbits[J].Anitimicrob Agents Chemother,2001,45 (2):612-615.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部